Healthcare shares are mixed in pre-market trade. Johnson &
) is up 1.3% as it reports Q3 adjusted EPS of $1.36, ahead of the
analyst consensus of $1.32 per share on Capital IQ. Sales were
$17.6 billion, vs. expectations of $17.4 billion.
The company increased its earnings guidance for full-year 2013
to $5.44 - $5.49 per share. The Street is at $5.46 per share.
And, Omeros (
) said that the U.S. Food and Drug Administration has approved its
study plan for the use of its OMS302 drug in pediatric patients
undergoing primary cataract extraction. A successful completion of
the plan would make the drug eligible for additional six months of
marketing exclusivity in the U.S.
The drug is designed to maintain interoperative pupil dilation,
prevent surgically induced pupil constriction and reduce
postoperative pain resulting from cataract and other lens
OMER closed down 2.12% on Monday. The stock is trading at the
top end of the 52-week range between $3.65 and $13.76.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.